威尼斯人
医学
嵌合抗原受体
白血病
免疫疗法
免疫学
肿瘤科
慢性淋巴细胞白血病
免疫系统
作者
Mazyar Shadman,David G. Maloney
标识
DOI:10.1016/j.hoc.2021.03.011
摘要
Despite significant improvement in clinical outcomes of chronic lymphocytic leukemia (CLL), patients who experience failure of Bruton tyrosine kinase inhibitors or venetoclax benefit from immune therapy approaches. Allogeneic transplant is a potentially curative treatment of CLL but is associated with risk of morbidity and mortality. Although still experimental, chimeric antigen receptor T-cell therapy provides durable remissions in patients with deep molecular responses. This review summarizes the relevant literature and discusses an approach to treatment sequencing and timing of referral for immune therapy. Novel immunotherapy approaches are being investigated and potentially can be utilized in sequence or combination with targeted agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI